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Abstract
Background: Hepatocellular carcinoma (HCC) represents a fifth of common
malignancies, with an annual diagnosis of 750,000 new cases. It is the third cause
of cancer deaths worldwide. The cirrhotic liver is a leading cause of HCC with the
annual conversion rate to HCC in the range of 2–6 %. The underlying liver cirrhosis
limits certain treatment modalities that potentially further aggravates liver dysfunction.
Over the past decade, there were substantial improvements in the HCC resection
techniques that has resulted in the reduction of operative mortality. This allowed doing
major hepatectomy in cirrhotic patients who are suitable for liver transplantation but
lacking availability of cadaveric or living donors. Also, patients who have multi-focal
HCC underlying cirrhosis which render them unsuitable for liver transplantation due
to its extension beyond Milan criteria.
Objective: The objective of this study was to assess the benefits and selection
criteria of HCC surgical resection within child–Turcotte–Pugh score (CTP) A and B
liver cirrhosis to achieve the best surgical outcomes.
Methods: We performed a literature search within English written trials using PubMed
and MEDLINE reviews databases from 1986 to 2017. One hundred fifty studies are
included in this review evaluating various parameters including HCC and compensated
cirrhosis prevalence, pathogenesis, clinical presentation, and diagnostic methods.
Furthermore, we have compared oncological hepatic resection with other modalities
like transarterial chemoembolization, liver transplantation, embolization of the portal
vein, laparoscopic hepatic resection, and ALPPS technique. Principles of surgical
hepatectomy and postoperative complications are also presented in this review.
Conclusion: This review has demonstrated that hepatic cirrhosis complicated by portal
hypertension is not an absolute contraindication for HCC resection. Furthermore,
elective surgery must not be directed exclusively to CTP A cirrhosis but it can
be applied to highly selected patients who had suffered from advanced hepatic
cirrhosis. If multifocal HCC underlying hepatic cirrhosis was unsuitable for liver
transplantation, hepatectomy can be carried out to increase the tumor cure chances,
prevent it’s recurrences, and lead to significant survival rate improvement. The degree
of cirrhosis significantly affects the decision of primary hepatic carcinoma treatment
and it’s prognosis. The interdisciplinary assessment of liver function by surgeons,
hepatologists, anesthesiologists, and specialists of critical care are essential for
maximum critical stabilization of the patients.
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1. Introduction
A significant increase in CTP A and CTP B cirrhotic patients complicated by portal
hypertension who requiring surgical resection was observed. This is due to several
reasons. First, cirrhosis is relatively common. During 2012, more than three million and
14.1 million new cases were diagnosed in Europe and globally respectively [1]. Over
the past decades, significant progress in liver disease management was obtained but
liver cirrhosis is still a major health disease belong to annually about 14-26 per 100,000
suffered from cirrhosis of which 170,000 died of its complications [2, 3]. Second, liver
cirrhosis is a leading cause of hepatocellular carcinoma (HCC) [4, 5]. Finally, liver cirrhosis
and HCC share certain risk factors such as alcohol abuse, smoking and metabolic
diseases [6–9].
2. Methods
2.1. The pathogenesis of HCC in underlying cirrhotic liver
Liver cirrhosis represents a wound healing response to chronic liver injury and shows
a prevalence of 250 patients per 100,000 persons [10, 11]. It’s characterized by liver
parenchymal distortion and is associated with nodular formation, fibrous septae and
blood flow alterations [12]. The fibrosis natural course starts with a long-lasting asymp-
tomatic compensated phase followed by rapidly progressive decompensated cirrhotic
phase characterized by liver function impairment [13, 14]. The median survival time of
decompensated cirrhosis is significantly shorter than compensated cirrhosis (2 years vs
>12 years) [13, 15]. In cirrhotic patients, about 5-30% develop HCC within a cumulative
five years [16, 17]. The annual conversion rate to HCC arising in cirrhotic patients is two
to six percent [18]. HCC represents the third cause of cancer deaths worldwide and the
fifth common malignancy with an annual diagnosis of 750,000 new cases. In Asia, the
risk is 35-117 per 100,000 annually, where in the USA the risk is only 7 per 100,000
persons per year [19]. In addition, 75-80% of HCC cases were due to infection by long-
term hepatitis B virus (50-55%) or hepatitis C virus (25-30%) [20–23]. Primary biliary
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cirrhosis, hereditary hemochromatosis, chronic alcohol abuse, diabetes and obesity
were also recognized as important risk factors [24–29].
2.2. Clinical presentation of compensated liver cirrhosis and HCC
Compensated cirrhosis defined as detection of clinical hepatic complications without a
possibility to be reversed in patients not having symptoms that indicate cirrhosis. These
complications include HCC, portal hypertension, esophageal varices, ascites, jaundice
and hepatic encephalopathy. It can be discovered clinically through hepatomegaly,
palpable left liver lobe and the enlarged spleen [30–33]. HCC prevalence was found to
be dominated by males within all etiologies, with an average age of 50 years. Symptoms
of HCC appear in the form of vague right hypochondrial pain, unidentified fever origin,
lethargy, anorexia, weight loss and nausea. Clinically HCC related signs are obstructive
jaundice and hepatomegaly [24–29, 34].
2.3. Diagnosis of compensated liver cirrhosis and HCC
Nowadays, the continuous improvements of diagnostic techniques using laboratory
tests in combination with radiological images, permits early diagnosis of liver cirrhosis
prior to the development of portal hypertension and HCC [35]. The laboratory findings
which help in the diagnosis of compensated cirrhosis are bilirubin >1.1 mg/dL, elevated
AST/ALT ratio, serum albumin <2.5 g/dL, platelet count <150,000/L, prothrombin time
<100% and increased alkaline phosphatase level [33]. OGD must be done to assess the
size and severity of esophageal varices and prevent their bleeding in future [32]. Fur-
thermore, HCC diagnosis often depends on serological tumor marker alpha-fetoprotein
(AFP) which is sensitive by 25% in a malignant lesion less than 3 cm in diameter to
fifty percent for tumors more than 3 cm as shown by radiological images [36]. In
suspected patients with cirrhosis, abdominal ultrasound shows the nodular surface
of the liver and the portal vein mean velocity less than 12 cm/second. Other signs
which suggest cirrhosis are left lobe with caudate hypertrophy, segment IV atrophy,
gallbladder fossa expansion, the presence of portosystemic collaterals, perihepatic
minimal ascites, dilated portal vein above or equal to 13 mm, dilated splenic vein and
superior mesenteric vein above or equal to 11 mm and enlarged splenic diameter above
12 cm. Moreover, because abdominal ultrasound is associated with low sensitivity, these
signs cannot allow a full exclusion of cirrhosis in patients with chronic compensated liver
disease [37, 38]. Fibroscan (elastography) is another test which helps in the assessment
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of hepatic stiffness and exclusion of cirrhosis caused by multiple different causes. A
score of more than 12.5 kPa has an accuracy of more than 90% to diagnose liver cirrhosis
[39, 40]. The previously mentioned ultrasound signs of hepatic cirrhosis can be revealed
by cross-sectional imaging including contrast-enhanced computed tomography scan
(CT) in portal venous phase and magnetic resonance imaging (MRI) which are precise
in the diagnosis of cirrhosis with a variable success rate [41, 42]. Also, imaging studies
are requested for planning oncological treatment and follow-up of metastatic recurrence
[43]. American Association for the Study of Liver Disease (AASLD) and European Asso-
ciation for the Study of Liver (EASL) guidelines recommend abdominal ultrasound as
surveillance study. If the ultrasound image shows suspicious nodules in cirrhotic liver
below 1 cm then these nodules are re-examined two times per year. In the absence of
nodular changes over two years, annual surveillance was recommended [44, 45]. Some
authors recommended that a screening strategy of combined abdominal ultrasound
and serum alfa-fetoprotein measurement every 6-months reduced HCC mortality rate
by forty percent [46]. If HCC with a size between 1-2 cm discovered in hepatic cirrhosis
by enhanced CT or MRI, images will show a high arterial contrast uptake followed by
rapid washout in the late stage (Figures 1, 2) [47].
Figure 1: Contrast-enhanced CT scan image of small HCC nodule in cirrhotic liver.
Currently, the HCC diagnosis often depends on cross-sectional imaging rather than
angiography [48]. The EASL recommended histological biopsy is not mandatory in HCC
diagnosis if HCC nodule on MRI or CT angiography is found to be more than 2 cm
in diameter with AFP elevation in sequential measurements or more than 400 ng/mL
[45, 49]. On the other hand, liver biopsy is commonly requested for hepatic cirrhosis
of unknown etiology [50]. In the early diagnostic phase of HCC, the positron emitting
tomography (PET) scan is not suitable except in suspicion of extra-hepatic metastases
that are not seen on CT or MRI images [51].
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Figure 2: MRI image of small HCC nodule in hepatic cirrhosis.
2.4. Surgical management of HCC in a compensated cirrhotic liver
2.4.1. Management overview
The nature of underlying liver cirrhosis limits certain treatment modalities. Hence, the
oncological staging of HCC must include cancer prognosis and liver function values
when selecting patients for surgical resection [52, 53]. Currently, the American and
European Liver Associations use the Barcelona Clinic Liver Cancer (BCLC) staging
system [28]. In the 1980s, Surgical removal of HCC within cirrhosis was a major surgery
with a mortality rate of 15-30% and was limited largely to segmental or sub-segmental
hepatectomy [54, 55]. Later, the operative mortality rate declined to 15% due to improve-
ments in major hepatectomy techniques [56–58].
2.4.2. Benefits of oncological hepatic resection
HCC resection aimed at radical removal of the tumor and morbidity reduction. There-
fore, patient selection is crucial [13]. After hepatic resection, operative mortality range
between three to eight percent and the five years survival rate reached thirty to fifty
percent [59]. In a large series of 22800 of hepatectomy cases, 22% were free from HCC
recurrence over ten years [60].
Hepatic resection for HCC has several advantages:
1. Compared to liver transplantation it requires no waiting time and is performed in
any well prepared medical centers.
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2. The resectioned tumor can be diagnosed histopathologically. Hence, it determines
the prognosis [61].
3. Hepatic resection can be performed as rescue therapy for HCC recurrence and/or
liver failure while waiting for future liver transplantation [62–64].
A current study of 2046 hepatectomy patients performed in ten large liver centers,
revealed that 50% of operated patients had BCLC stage A without portal hypertension,
while 36% and 14% had hepatectomy in BCLC stage B and C, respectively [65]. The
overall 5-years survival post-hepatectomy in BCLC stages including A, B and C cirrhosis
were 61%, 57% and 38% and five years free of recurrence were 21%, 27% and 18%
respectively. Thus, HCC resection had reasonable long-term outcome in advanced
cirrhotic stages [66, 67].
2.4.3. Selection of candidates for oncological hepatic resection
Hepatectomy is frequently performed within cirrhosis in presence or absence of portal
hypertension in spite of metastatic risk reduction by cirrhosis [68, 69]. Hepatectomy
has been indicated for non-portal hypertensive patients with single tumor nodule and
normal bilirubin measurement according to EASL and AASLD HCC guidelines treat-
ment [70]. Furthermore, BCLC suggests HCC curative hepatectomy only in non-portal
hypertensive CTP A cirrhosis and in tumor in early stages [76]. In contrast, multiple
publications worldwide revealed that hepatectomy for HCC within cirrhotic liver with
portal hypertension can give a good life span expectancy [67, 71, 72]. Torzilli et al.
showed that about 50% of hepatectomies with cirrhotic liver done beyond BCLC criteria
is associated with overall five years survival of 57% and 38% for stage B and stage C
patients respectively [65]. Also, gives an excellent long-term survival rate compared
to transarterial chemoembolization (TACE) and HCC resection can be offered to cases
beyond BCLC criteria [73–76]. Yin et al. revealed in a study of 173 patients that suffered
from HCC beyond the Milan criteria, liver resection patients have a significant better
long-term survival rate of 51.5% for three years, vs 18.1%when compared to TACE. Hence,
complicated liver cirrhosis with portal hypertension must not be denied HCC hepate-
ctomy [76]. Furthermore, neoadjuvant TACE therapy has been failed in improvement
of survival rate for HCC underlying cirrhotic cases despite its initial promising results
[77]. Ishizawa et al. showed excellent predictors of HCC resectability in spite of portal
hypertension depending on a combination of bilirubin, ascites and indocyanine green
clearance [71].
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The followings are the criteria for selecting the candidates for liver resection:
1. Rule out of extrahepatic metastases
The performance of chest CT scan prior to resection is desirable, due to lymph
nodes, lungs or bone metastasis [78].
2. Evaluation of HCC extent
HCC site, size, account and proximity to major vessels all influence the respectabil-
ity. CTP A cirrhotic patients may tolerate major hepatic resection, while CTP B
patients tolerate a safe minor resections. Tumor size precisely may not indicate
safe hepatectomy and some authors reported that tumors above ten centimeters
had more than 45% five years survival [79]. HCC invasion of a biliary tree or main
vessels might be a contraindication for resection, except portal vein involvement
or hepatic segmental thrombosis [80]. Multinodular tumors have a poor prognostic
ratio, reoccur within 80–100% of patients and thirty percent of them survive for
five years. If hepatic transplantation is not feasible multinodular tumors might be
respectable [81, 82].
3. The liver functional reserve estimation
• Determining of functional residual liver volume after oncological resection
The least residual hepatic volume in non-chronic liver disease patients needed
for the avoidance of advanced hepatic dysfunction postoperatively was twenty
to thirty percent [82]. In the 1990s, very few studies analyzed cirrhotic patients
for the role of future remnant hepatic volume prognosis. Shirabe et al. have
studied chronic liver disease in 80 patients and fifty percent of them suffered
from cirrhosis did a major hepatectomy and revealed that liver failure deaths
happened when a remnant hepatic volume less than 250 mL/m2 body surface
and concluded that safe limit of major hepatectomy depending on functioning
residual volume of the liver. Currently, highly resolution CT volumetry scan can
measure residual volume that is accepted for safe hepatectomy which is 30%
in non-cirrhotic liver disease and 40% in CTP A cirrhosis not complicated by
portal hypertension [83, 84]. In 2012, the associating liver partition and portal
vein ligation for staged hepatectomy (ALPPS) technique was first published for
raising the resection chances of inoperable HCC through rapid hypertrophy
of the future liver remnant (FLR) which reduces postoperative liver failure risk.
This technique was indicated when FLR reached up to 30% or 40 % in case
of chemotherapy complicated by hepatic injury, colorectal liver metastases,
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hilar cholangiocarcinoma, gallbladder cancer, primary hepatic lymphoma and
18% of surgeons suggested this technique for CTP A cirrhotic patients. The
disadvantages of ALPPS technique are perioperative morbidity is 68% and
postoperative mortality is 12% at 6 months. Biliary fistula and adhesions can
complicate the ALPPS first stage. Moreover, it was contraindicated in extra-
hepatic distant metastases, patients beyond 75 years old, macrovesicular
steatosis above 50% and CTP B or C cirrhosis is considered as an absolute
contraindication especially if combined with HCC as chronic liver damage has
less cellular regeneration [85].
• Assessment of liver function
For more than forty years the Child-Turcotte-Pugh score known as a gold stan-
dard grading system for the liver function to select candidates for hepatectomy
and predict prognosis after surgeries for portal hypertension like portocaval
shunt and transection of the esophagus in cirrhotic patients. There is general
agreement that surgical resection can be performed safely and should be
considered as a beginning treatment for solitary tumors within CTP A cirrhosis
[85–88]. Alternative therapies including liver transplantation must be sought
for CTP B or C hepatic cirrhosis not suitable for major hepatectomy [89–
91]. Hence, according to the BCLC algorithm current version, HCC treatment
depends on the underlying cirrhotic severity graded by CTP classes [28, 92].
The original score was slightly modified later using the INR, serum biliru-
bin, serum albumin, hepatic encephalopathy and ascites which classifies the
patients into compensated CTP A, mild CTP B and severely decompensated
CTP C cirrhosis. The survival rate of one year for CTP A is 95%, CTP B is
80% and CTP C account forty-four percent [13, 93]. The model for end-stage
liver disease (MELD) score has been established for candidates selection
into liver transplantation and survival prediction of transjugular intrahepatic
portosystemic shunt (TIPS) patients. It’s measured from bilirubin, INR and
creatinine [89, 94]. Currently, it is correlated with postoperative resection
outcomes and hepatectomy candidates selection. If the score was more than
nine, this generally was associated with higher postoperative liver failure rates
[89, 91]. Other studies revealed if the score is equal or less than ten, this
means patients are suitable for partial hepatectomy [87, 95, 96]. In Asia, the
clearance test of indocyanine green (ICG) is an acceptable test for the liver
function. After intravenous dye injection, the rate of retention at 15 minutes
(ICGR15) for the normal liver function is 10%. Safe major hepatectomy is
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allowed when ICGR15 is equal to or less than fourteen percent [57]. The cut-
off ICGR15 for minor hepatectomy is 22% and ICGR15 values up to 40% were
suitable for limited resection [97–99]. Sixty-five percent of patients with CTP B
showed an ICGR15 less than twenty-two percent. This test is most applicable
to a small hepatectomy; therefore, it is perfect for patients with CTP B who
require segmental hepatectomy. A recent study compared the prognosis of
MELD score with ICGR15 in 395 patients suffering from cirrhosis did not have
surgery revealed the ICGR15 was more precise in survival prediction [100].
Furthermore, the Japanese HCC clinical guidelines recently recommended a
preoperative ICGR15 usage for evaluation of the liver function [101].
• Assessment of portal hypertension
Portal hypertension clinical signs reflect a deterioration of liver disease fol-
lowing hepatectomy, and also poor long-term outcome. In other words, portal
hypertension determines the success rate of surgical resection. The BCLC
guidelines had recommended hepatectomy only for non-clinical significant
portal hypertension patients which can be assessed by hepatic vein-portal
gradient (HVPG) less than 10 mmHg [28]. This invasive direct method may
not be available everywhere. Also, the BCLC determines portal hyperten-
sion signs clinically by many indirect clinical tests: endoscopic esophageal
varices or enlarged spleen described as more than 12 cm in diameter with
platelets count less than 100,000/mm3. Some authors recommended that
hepatectomy was contraindicated if these signs appear [92, 102]. Currently,
portal hypertension must not be considered as an absolute contraindication
for hepatectomy within well-compensated CTP A cirrhosis or MELD score
below ten [67, 103]. Complications of portal hypertension like variceal rupture
bleeding and hemostatic disorders due to thrombocytopenia can safely be
treated [104, 105].
4. Comorbidities of other organs
Severe comorbidity like congestive cardiac failure and chronic renal failure must
be considered as contraindications for surgical removal of HCC. Diabetes mellitus
is common in patients that suffer from cirrhosis and recently a report showed
post-hepatectomy morbidity and mortality in these patients [106, 107].
Hence, the guidelines in western countries currently recommend resection exclu-
sively for cirrhotic cases have well-preserved liver function determined by normal
bilirubin levels in serum associated with HVPG ≤10 mmHg or platelets number
≥100×109 per liter. By following these strict criteria, the liver resection can be
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applied only in 5–10% of all patients with HCC [108]. Moreover, patients who had
liver resection with normal serum bilirubin levels and non-clinical significant portal
hypertension (CSPH) can reach 70% of five years survival, while those with CSPH
reach about fifty percent. Prognosis is worse in CSPH patients who have elevated
bilirubin [71, 109].
2.4.4. Preoperative therapy of oncological hepatic resection
1. Antiviral therapy of chronic hepatitis B virus (HBV)-related HCC patients:
The preoperative antiviral therapy of chronic hepatitis B virus-related HCC patients
is essential, leading to improved liver function and reduce progression chances into
cirrhosis. It decreased HCC incidence in these patients, prolonging overall survival
after curative and palliative modalities which delay HCC recurrence in patients
treated for 3 years (1.5% vs 4.0%) and 5 years (5.1% vs 12%) rather than those without
treatment [110]. If HBV-DNA was detected, then 1-3 months preoperative therapy
must begin. Entecavir and tenofovir disoproxil are recommended as first-line anti-
HBV drugs with high efficacy. Also, a combination of α-interferon and ribavirin had
reduced occurrence of HCC significantly. Administration of lamivudine, dipivoxil
or entecavir postoperatively had a significant reduction in HCC death and it’s
recurrence with an improvement of hepatic function six months later [110].
2. Embolization of the portal vein (EPV):
Before hepatic resection EPV is helpful in increasing residual volume of the liver
when extended hepatectomy is mandatory and when liver remnant volume is
inadequate [111–112]. Prospective studies revealed that an early outcome improve-
ment in patients who had right HCC hepatectomy with portal vein embolization
preoperatively. The complication rate of EPV is 10–20% and accelerated portal
hypertension can appear in 1% of cirrhotic patients [112–113]. EPV is relatively con-
traindicated if there are segmental portal occlusion/invasion, biliary obstruction,
coagulopathy and renal failure [114, 115].
2.4.5. Principles of surgical hepatectomy
Intraoperative bleeding is a major risk that determines the perioperative mortality.
The following are some points on the principles of surgical resection:
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1. Cooperative work with the anesthetic staff is mandatory throughout hepatectomy.
During parenchymal dissection, the blood loss is risky and is controlled by reduc-
tion of central venous pressure up to 5 mmHg by options including diuretics,
volume restriction, positive end-expiratory pressure, decreased tidal volume and
reverse Trendelenburg position [116, 117].
2. The hepatic hilar vascular occlusion (Pringle maneuver) may not be recommended
in cirrhosis. However, it is urgently used for prevention of extensive bleeding
during parenchymal dissection by intermittent occlusion for fifteen minutes then
five minutes of releasing (Figures 3, 4) [118, 121].
Figure 3: Intraoperative CUSA circumferential HCC resection in cirrhotic liver using intermittent hilar vascular
occlusion.
Figure 4: Adequate HCC resection margins within the cirrhotic liver using intermittent hilar vascular
occlusion.
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3. Hepatectomy that depends on anatomic Couinaud segments is not important, but
high care should be given to vascularized parenchyma preservation for prevention
of postoperative liver failure [122]. In particular, this maneuver might be useful in
cases with mild portal hypertension and advanced CTP B cirrhosis [123].
4. One centimeter wide margin is generally adequate. However, two centimeters
wide margin produces greater survival rate (Figures 5, 6) [122, 124, 125].
Figure 5: Postoperative circular hepatic tissue contained HCC mass.
Figure 6: Postoperative adequate resection margins of HCC mass.
5. Liver transection maneuvers that depend on a high tissue resistance discrimination
of bile ducts and blood vessels compared to the liver tissues include crushing dis-
sector instrument, water jet dissection, stapler dissection and cavitary ultrasound
suction aspirator (CUSA) (Figure 3) [126–129].
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6. The anterior approach may be beneficial in large tumors, where caval vein mobi-
lization may need traction or pressure on the tumor has a capability to cause
bleeding, rupture and tumor cells dissemination [130, 131]. This technique has been
helped by the hanging maneuver through blunt dissection to pass a band between
the right and middle hepatic veins and in front of the inferior vena cava. Band
traction makes a straight transection with bleeding control in its depths [132, 133].
Furthermore, fibrin glue application following hepatic resection is not beneficial
in controlling of blood loss and in a reduction of blood transfusion requirements
[134].
7. Current standards of liver resection describe 2-3% mortality rate and five-year
survival rate around sixty percent [135].
When comparing open hepatic resection and laparoscopic resection, 90% of laparo-
scopic resections were minor resections [136]. Because of the underlying liver disease,
post-HCC hepatectomy complications occur in fifty percent of cases [137]. Laparoscopic
hepatectomy advantages are minimal peritoneal dissection, less aggressive technique,
reduced ascitic fluid and liver failure [138, 139]. Furthermore, reduced laparoscopic post-
operative adhesions help in future liver transplantation salvage with less morbidity when
compared to open hepatectomy [140]. Major disadvantages which reducewidespread of
laparoscopic liver resection are difficulties in the transection of parenchyma and tissue
mobilization that may be associated with massive bleeding risk. In addition to greater
difficulty in performing anatomical resections and wide margin resection [141, 142].
2.4.6. Postoperative complications of oncological hepatic resection in
compensated cirrhosis
The hepatic resection in cirrhotic portal hypertension showed increased morbidity with
a range from twenty-two percent to fifty percent [67, 71, 72, 143]. These complications
arranged in the following points:
1. Postoperative life-threatening liver failure, which can be managed by remnant liver
optimal perfusion, prophylactic antibiotics and intensive care of electrolytes, fluid
balance, renal function, and coagulation [144, 145].
2. Ascites reduced after 5-7 days with the support of fluid volume restriction, diuretics
and albumin infusion. Ascitic fluid persistence needs microbiological test, early
detection and treatment of any infections [146].
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3. Suspected postoperative infection, mainly from chest pneumonia. Also, superin-
fected ascites can be treated by third generation cephalosporins like ceftriaxone
or cefotaxime, or carbapenems alternatively. Furthermore, sampling and micro-
biologic culture of ascitic fluid is advised before the start of antibiotic treatment
[147–149].
4. Disorders of wound healing noticed rather commonly due to malnutrition and for
postoperative ascites. A running suture during abdominal closure gives protection
against wound dehiscence. Also, a drainage system prevents fluid accumulation
with reduction of intra-abdominal pressure which leads to wound healing improve-
ment [150].
5. Postoperative hemorrhage in cirrhotic patients may include superficial wound
bleeding, resection site bleeding and gastrointestinal bleeding. Therapies that
include coagulation products supplementation are highly important [150].
In conclusion, this review has demonstrated that hepatic cirrhosis complicated by
portal hypertension is not an absolute contraindication for HCC resection. Furthermore,
elective surgery must not be directed exclusively to CTP A cirrhosis but it can be
applied to highly selected patients who had suffered from advanced hepatic cirrhosis. If
multifocal HCC underlying hepatic cirrhosis was unsuitable for liver transplantation, hep-
atectomy can be carried out to increase the tumor cure chances, prevent its recurrences
and lead to significant survival rate improvement. The degree of cirrhosis significantly
affects the decision of primary hepatic carcinoma treatment and it’s prognosis. The
interdisciplinary assessment of liver function by surgeons, hepatologists, anesthesiol-
ogists and specialists of critical care are essential for maximum critical stabilization of
the patients.
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